Wednesday, June 13, 2007

Sandoz to Step in as Authorized Generic

Novartis is likely to launch an authorized generic for Lotrel through its generic division Sandoz after the US District Court for the District of New Jersey vacated a restraining order against Teva Pharmaceuticals to halt shipments of generic versions of the drug in the US, which means now Teva can resume shipments of generic Lotrel. The New Jersey court also denied a Novartis motion for a preliminary injunction in an ongoing patent dispute. However, Novartis will continue pursuing its defense of patent rights as Lotrel has a US patent valid until 2017. Lotrel is combination of ACE inhibitor benazepril with calcium channel blocker amlodipine besylate, and had sales of US $ 1.35 billion in 2006.

No comments:

Post a Comment